Hepatitis B Vaccine

Biopharma company signs distribution agreement for hepatitis B vaccine in China

Published in Vaccine Weekly, November 9th, 2005

SciGen Ltd (SIE) announced the closure of a commercialization agreement with Hefei Life Science Park Investment & Development Co, (HID) for distribution of its hepatitis B product, Sci-B-Vac, in China which will generate revenue in excess of USD$145 million.

Under the agreement HID is required to order and pay for minimum annual quantities of Sci-B-VacTM, either as dispensed doses or bulk antigen, for 7 years. In the former case, the minimum allocation of final product per annum will generate revenues of USD $210 million for SciGen over 7 years. For bulk antigen, the 7-year order would total USD $145 million.

HID has been appointed as the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-11-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry